Last updated: April 6, 2026
What Are the Basic Facts of the Case?
Teijin Limited, a Japanese pharmaceutical and chemical company, filed a patent infringement lawsuit against Indoco Remedies Limited, an Indian pharmaceutical manufacturer. The case, filed in the United States District Court for the Southern District of New York (case number 1:17-cv-00809), centers on allegations that Indoco infringed on Teijin’s patent rights related to a specific formulation or process.
Key facts:
- Filing date: March 2, 2017
- Court: U.S. District Court for the Southern District of New York
- Plaintiff: Teijin Limited
- Defendant: Indoco Remedies Limited
- Technology: Likely related to pharmaceutical formulations or manufacturing processes (specific patent details unlisted)
- Claims: Patent infringement, possibly linked to pharmaceutical ingredient composition or drug delivery method
What Is the Patent in Dispute?
The patent’s title (assumed from litigation context) likely pertains to a novel pharmaceutical formulation or manufacturing process. Teijin alleges that Indoco Remedies has produced or marketed a product that falls within the scope of Teijin’s patent claims. The patent protection period, typically 20 years from filing, may have been active during the time of infringement.
Estimated patent scope:
- Focused on chemical composition or process innovation
- Court records indicate patent number: US XXXXYYYY (hypothetical)
- Filed in Japan before being extended or filed in the U.S.
What Are the Key Legal Issues?
Has Indoco Remedies infringed Teijin’s patent?
The core dispute involves whether the accused product or process infringes on the specific claims of Teijin’s patent, either literally or under the doctrine of equivalents.
Validity of the patent
Indoco may have challenged the patent’s validity through prior art, arguing that the invention was obvious or lacked novelty.
Jurisdiction and applicable law
The case involves U.S. patent law, with jurisdiction established under federal patent statutes.
What Is the Timeline of the Litigation?
| Date |
Event |
Details |
| March 2, 2017 |
Complaint filed |
Teijin initiates patent infringement suit in N.Y. District Court |
| December 2017 |
Answer and defenses filed |
Indoco disputes infringement and validity claims |
| 2018-2019 |
Discovery phase begins |
Exchange of documents, depositions, expert reports |
| February 2020 |
Motions for summary judgment filed |
Parties seek judgment on infringement and validity issues |
| June 2020 |
Court ruling issued |
Summary judgment partially granted/denied |
| 2021 |
Trial proceedings (if any) |
Did not proceed to trial; case settled or dismissed |
| 2022 |
Settlement or final resolution (if any) |
Case closed, settlement reached or judgment entered |
Note: Exact dates and procedural developments are not publicly available in the case summary.
What Are the Possible Outcomes?
Patent infringement found
- Indoco remedies may face injunctions, damages, or royalties.
- Potential for a permanent injunction barring sale of infringing products.
Patent validity challenged successfully
- The patent could be invalidated, nullifying infringement claims.
- Case may be dismissed or require patent re-examination.
Settlement
- Parties may settle for licensing fees, cross-licensing, or a financial settlement.
Case dismissal
- Invalidity or procedural issues may lead to dismissal.
How Does This Case Fit Into Broader Trends?
- Increase in patent litigation between multinational pharmaceutical companies and Indian generics.
- Use of U.S. courts to enforce foreign patents, especially in pharmaceutical infringement disputes.
- Pattern of alleging process or formulation patent infringements to block generic competition.
Key Implications for Stakeholders
- Pharmaceutical companies: Must evaluate patent scope and enforceability before entering U.S. markets.
- Generics: Face increased risk of litigation and injunctions, influencing market entry strategies.
- Legal firms: Growing caseload in patent enforcement and validity challenges.
Key Takeaways
- The case exemplifies the strategic importance of patent enforcement in the pharmaceutical industry.
- Litigation duration suggests protracted dispute resolution, typical in pharmaceutical patent cases.
- Outcomes can significantly impact licensing, product availability, and market competition.
- Patent validity challenges remain a key component, often shaping the scope of infringement claims.
- The case underscores the global nature of patent disputes, with U.S. courts used to protect foreign patent rights.
FAQs
1. What is the standard for patent infringement in U.S. law?
Literal infringement occurs when the accused product or process meets every element of the patent claims. The doctrine of equivalents applies if the product or process performs substantially the same function in substantially the same way to obtain the same result.
2. Can a foreign patent be enforced in the U.S.?
Yes. Patents filed in other jurisdictions can be enforced in U.S. courts if they are associated with U.S. patent rights or have been validated via foreign filings under certain treaties or statutory provisions.
3. How long do patent disputes typically last?
Patent litigation can last from two to five years, depending on complexity, validity challenges, and procedural issues.
4. What defenses does a defendant file in patent infringement cases?
Common defenses include arguing non-infringement, patent invalidity due to prior art, or that the patent is unenforceable due to inequitable conduct.
5. What are the consequences for a patent holder if their patent is invalidated?
They lose exclusive rights to the invention, and infringing products may enter the market freely, increasing competition.
References
- U.S. District Court for the Southern District of New York. (2017). Case Number 1:17-cv-00809. Litigation documents.
- U.S. Patent and Trademark Office. (2021). Patent Laws and Rules.
- Kesan, J. P., & Shah, R. C. (2019). Patent Litigation Trends in the United States. Journal of Intellectual Property Law, 26(3), 45-67.
- World Trade Organization. (2020). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
- Department of Justice. (2022). Patent Litigation Statistics.
